IRCCS Istituto Nazionale Tumori Fondazione Pascale

At IRCCS Istituto Nazionale Tumori Fondazione Pascale in Naples, the strongest focus is on neoplasms and a wide range of solid tumors, including breast, lung, ovarian, colorectal, gastric, pancreatic, melanoma, and urothelial cancers. These studies are designed to test new treatment options, improve disease control, and compare emerging therapies with current standards of care.

• Breast cancer, ovarian cancer, melanoma, and lung cancer are among the most frequently studied diseases
• Research includes advanced, metastatic, recurrent, and high-risk early-stage cancers
• Many trials evaluate whether newer therapies can improve survival and reduce recurrence

Much of the research at this site centers on refining cancer treatment strategies for patients with difficult-to-treat or advanced disease.

This site has extensive activity in female urogenital diseases and hormone-driven cancers, especially breast cancer, endometrial cancer, ovarian cancer, cervical cancer, and related gynecologic malignancies. The trials are mainly aimed at improving treatment effectiveness, reducing relapse risk, and identifying better options for patients whose disease has returned or become resistant to standard therapy.

• Hormone receptor-positive and HER2-positive breast cancer are major areas of study
• Ovarian, endometrial, and cervical cancers are also strongly represented
• Several studies focus on recurrent, metastatic, or treatment-resistant disease

These investigations reflect a strong interest in personalized cancer care for women’s cancers.

The Department of Urology and Gynecology supports a substantial portfolio in male urogenital diseases and urinary tract cancers, especially prostate cancer, bladder cancer, urothelial carcinoma, and renal cell carcinoma. The main purpose of these trials is to evaluate new treatments, improve outcomes in advanced disease, and explore better approaches for patients who have limited standard options.

• Prostate cancer studies include both castration-sensitive and castration-resistant disease
• Bladder and urothelial cancer research covers non-muscle-invasive, muscle-invasive, and metastatic settings
• Renal cell carcinoma is another recurring focus, including advanced and metastatic forms

The site’s urologic research is centered on practical advances that may help extend disease control and support long-term management.

There is also broad work in respiratory tract diseases and digestive system diseases, with many trials in non-small cell lung cancer, small cell lung cancer, colorectal cancer, gastric cancer, pancreatic cancer, and hepatocellular carcinoma. These studies commonly aim to improve survival, test combination treatment strategies, and identify more effective care for advanced or unresectable disease.

• Non-small cell lung cancer is one of the most prominent research areas
• Colorectal, gastric, pancreatic, and liver cancers are also well represented
• Several studies explore treatment options for recurrent, metastatic, or biomarker-defined tumors

Overall, this research landscape shows a strong commitment to developing better cancer therapies across major thoracic and gastrointestinal malignancies.

Another important area at this hospital/clinic is skin and connective tissue diseases, especially melanoma, cutaneous squamous cell carcinoma, and basal cell carcinoma. The clinical trials here are focused on testing new immunotherapy and targeted treatment approaches, with the goal of improving response rates and preventing recurrence in both advanced and surgically treatable disease.

• Melanoma research includes metastatic, unresectable, and high-risk resectable disease
• Skin cancer trials also address basal cell carcinoma and cutaneous squamous cell carcinoma
• Some studies aim to strengthen outcomes after surgery or in patients resistant to earlier treatment

This area highlights a clear interest in advancing more effective and durable treatment strategies for skin cancers.

The site also conducts research in hemic and lymphatic diseases, with trials in lymphoma, multiple myeloma, and other blood cancers. These studies are generally designed to evaluate new therapies, improve outcomes after relapse, and support better disease control in patients with aggressive or hard-to-treat hematologic malignancies.

• Diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma are key areas
• Research also includes Hodgkin’s lymphoma, peripheral T-cell lymphoma, and multiple myeloma
• Several trials focus on relapsed or refractory disease, where treatment choices are more limited

These studies broaden the site’s cancer portfolio beyond solid tumors and into specialized blood cancer care.

Across multiple programs, IRCCS Istituto Nazionale Tumori Fondazione Pascale is also active in diagnostic techniques, therapeutics, and biomarker-focused oncology research. Many trials are built around identifying which patients are most likely to benefit from a given treatment, helping to improve precision medicine in everyday cancer care.

• Biomarker-driven studies include HER2, PD-L1, ESR1, BRCA, KRAS, BRAF, and other molecular targets
• Some trials evaluate whether circulating tumor DNA can help track treatment benefit
• Research also includes studies aimed at better matching therapies to tumor biology

This translational approach supports more individualized treatment selection across several cancer types and therapeutic areas.